The Asia-Pacific scar treatment market size was valued at $3.6 billion in 2016, which is forecasted to reach $7.8 billion by 2023, growing at a CAGR of 11.6% during the 2017-2023. Among the various types of scar treatments, topical scar treatment is expected to lead the scar treatment market in the region, followed by surface, laser, injectable, and invasive surgical treatment. Increasing focus on personal well-being, rising awareness about scar treatments and growing availability of non-invasive and less expensive topical scar treatment products are expected to be the drive the demand for topical scar treatment products.
Get Sample Copy of this Research Report@ https://www.psmarketresearch.com/market-analysis/asia-pacific-scar-treatment-market/report-sample
Hospitals were the largest end user in the regional market, mainly due to increasing healthcare expenditures by government and improving healthcare infrastructure. The other end users in the include private clinics, pharmacies & drug stores and e-commerce websites.
The growing awareness about various scar treatments available is driving the market demand in the region. Also, the growing adoption of the OTC scar treatment products, which are priced below the prescription drugs is another factor boosting the demand for scar treatment products in Asia-pacific. Additionally, the presence of advanced laser treatments and surgeries also enables the treatment of all types of scars in comparatively lesser time. The high cost of scar treatment products is the major factor hindering the growth of the market in the region.
The key players operating in the Asia-Pacific scar treatment market include Shanghai Fosun Pharmaceutical (Group) Company Limited, Beijing Toplaser Technology Company Limited, Sirnaomics, Inc., Essex Bio-Technology Limited, A. Menarini Asia-Pacific Holdings Pte. Ltd, Shiseido Company Limited, Concord Medisys Pvt. Ltd, Seoulin Bioscience Co. Ltd., Hanson Medical Inc., Otsuka Pharmaceutical Co., Ltd.